Connect with us
European Gaming Congress 2024

Latest News

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Published

on

HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.

 

 

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”

Advertisement
Stake.com

Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.

Advertisement
Stake.com

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected] 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Advertisement
Stake.com

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Advertisement
Stake.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs-302169232.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Setgaji Launches in Malaysia, Leading Global Financial Wellness

Published

on

KUALA LUMPUR, Malaysia, June 18, 2024 /PRNewswire/ — Prepare for a paradigm shift in financial empowerment with Setgaji Sdn. Bhd.’s groundbreaking platform, Setgaji. This innovative solution redefines how financial wellness is managed, setting a new standard for accessibility and empowerment.

Setgaji leads the charge towards a brighter future by revolutionising the timing and accessibility of salary withdrawals. This platform not only simplifies processes but also enhances employee motivation and satisfaction, creating rewarding work experiences.

More than just a tool, Setgaji is a movement committed to empowering individuals and transforming workplace practices. By providing early access to earned wages, Setgaji enables healthier financial habits and eliminates the need for high-interest loans for Malaysians in the workforce.

Unique to Setgaji is its pioneering feature as Malaysia’s earned wage access platform that is completely free for both employees and employers. This transparency ensures no hidden costs for employees while employers benefit from earning air miles with each transaction.

“We are excited to introduce Setgaji to the global stage, where financial wellness is our ultimate goal for the workforce,” said Mr. Micheal Ngu Kiet Ting, COO of Setgaji Sdn. Bhd. “Our platform signifies a revolutionary approach to financial management, offering employees autonomy in today’s fast-paced world.”

Advertisement
Stake.com

The pathway for a transformative journey towards financial wellness is here. Discover how Setgaji reshapes the landscape of financial practices at www.setgaji.com

About Setgaji Sdn. Bhd.

Setgaji Sdn. Bhd. is a dynamic financial solutions provider, specializing in early wage access services for employees. Since 2024, we have established ourselves as a trusted authority in pioneering financial solutions, addressing cash flow challenges and promoting employee financial well-being. Our mission is to reshape financial practices and foster sustainable financial habits among employees through innovative solutions tailored to modern organizational needs.

Photo – https://mma.prnewswire.com/media/2441386/Press_Release_Image__1.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/setgaji-launches-in-malaysia-leading-global-financial-wellness-302175415.html

Advertisement
Stake.com
Continue Reading

Latest News

Stax Opens New Central London Office Amidst Rapid U.K. Expansion

Published

on

NEW YORK, June 18, 2024 /PRNewswire/ — Stax LLC, a global strategy consulting firm specializing in commercial due diligence, value creation, and exit planning for private equity firms, PE-backed companies, hedge funds, and investment banks, today announced the opening of a new office in Central London. This expansion follows the January hiring of Phil Dunne as managing director to lead the firm’s U.K. and EMEA practice and strategic growth efforts. Aiming to double its headcount by 2025, Stax quickly outgrew its previous space in less than a year and sought new premises to accommodate its rapid expansion in the U.K. market. Stax’s substantial growth with U.K. and European private equity clients, coupled with its team expansion, underscores the enduring appeal of the U.K. mid-market—particularly in the M&A landscape and private equity ecosystem.

“It’s exciting to witness Stax expanding once again in London. As I lead our U.K. and EMEA growth strategy, we are keenly focused on strengthening our brand in the local market,” stated Phil Dunne, U.K. Managing Director. “We have recently achieved significant accolades, such as being named a finalist in the 2024 Real Deals Private Equity Awards for Commercial Due Diligence Provider of the Year. Additionally, we just won the U.S. SME Growth and Investment in the U.K. award at the BritishAmerican Business Transatlantic Growth Awards.”

Dunne elaborated, “Another key objective is team expansion, with the goal of doubling our headcount by 2025. As Stax broadens its sector expertise, we are actively recruiting at all levels with a special emphasis on strategic senior roles, particularly in healthcare and consumer verticals. This will enable us in London to provide our clients with a comprehensive portfolio of specialized experts spanning across technology, industrials, business services, healthcare, consumer and retail, and information services.”

“This year, as we celebrate the 30th anniversary of Stax, we’re excited to be closer to our London-based clients to better serve their needs. We continue to deliver transaction advisory services to our extensive roster of U.S.-based clients who are rapidly entering into the U.K. market, as well as our U.K. and EMEA-based clients expanding into the U.S. market. By supporting both sides of this dynamic ecosystem, Stax is experiencing significant growth,” shared Paul Edwards, Global Practice Leader. “We are committed to our U.K. growth strategy and leveraging it to drive our expansion across Europe, fueled by substantial growth in our European private equity engagements from clients who value our unique, data-driven advisory offerings.”

As Stax strives to deliver the highest level of service to our clients, the company is also dedicated to strengthening its European team and providing employees with expanded resources and opportunities for professional growth and development. Stax is hiring across levels, with a particular focus on senior leaders with healthcare and consumer expertise. Those interested in joining a dynamic organization and a growing U.K. team are encouraged to apply now.

Advertisement
Stake.com

About Stax LLC 

Stax LLC is a global management consulting firm serving corporate and private equity clients across a broad range of industries including software/technology, healthcare, business services, industrial, consumer/retail, and the events ecosystem. The firm partners with clients to provide data-driven, actionable insights designed to drive growth, enhance profits, increase value, and make better investment decisions. Please visit www.stax.com and follow Stax on LinkedIn, Instagram, Threads, and Facebook. 

Logo – https://mma.prnewswire.com/media/2428526/Stax_logo_w_tagline_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/stax-opens-new-central-london-office-amidst-rapid-uk-expansion-302173350.html

Continue Reading

Latest News

Millionaires on the Move: Where are the World’s Wealthy Migrating to and from in 2024?

Published

on

LONDON, June 18, 2024 /PRNewswire/ — The UK is expected to see an unprecedented net loss of 9,500 millionaires in 2024 — second only to China worldwide, and more than double the 4,200 who left the country last year, which was itself record-breaking following the exodus of 1,600 HNWIs in 2022. For the third year running, the UAE looks set to take first place as the world’s leading wealth magnet, with a record-breaking 6,700 moneyed migrants expected to make the Emirates home by the end of the year, boosted by large inflows from the UK and Europe.

The Henley Private Wealth Migration Report 2024, released today by international investment migration advisory firm Henley & Partners, features the most significant projected millionaire migrant inflows and outflows globally as well as the W15 ranking of the world’s top 15 countries for millionaires, centi-millionaires and billionaires. 

China is again on track to be the biggest millionaire loser globally, with an anticipated net exit of 15,200 HNWIs this year (compared to 13,800 in 2023) whereas India has stemmed its wealth exodus, dropping down to 3rd place after the UK with just 4,300 millionaires projected to leave the country in 2024 (compared to 5,100 last year). South Korea’s HNWI flight is expected to rise with a forecast loss of 1,200 millionaires (compared to 800 in 2023) while the tsunami of millionaires that fled Russia following the outbreak of the Ukraine war appears to be abating with only 1,000 projected to relocate this year (compared to 8,500 in 2022 and 2,800 in 2023).

Dominic Volek, Group Head of Private Clients at Henley & Partners, says 2024 is shaping up to be a watershed moment in the global migration of wealth: “An unprecedented 128,000 millionaires are expected to relocate worldwide this year, eclipsing the previous record of 120,000 set in 2023. As the world grapples with a perfect storm of geopolitical tensions, economic uncertainty, and social upheaval, millionaires are voting with their feet in record numbers.”

UAE remains world’s leading millionaire magnet

Advertisement
Stake.com

With its zero income tax, golden visas, luxury lifestyle, and strategic location, the UAE has entrenched itself as the world’s number one destination for migrating millionaires and is poised to attract nearly twice as many millionaires as its nearest rival, the US, which is projected to benefit from a net inflow of 3,800 millionaires in 2024.

Singapore takes 3rd prize again this year with net inflows of 3,500, while the perennially popular destinations for migrating millionaires, Canada and Australia, follow in 4th and 5th places with net inflows of 3,200 and 2,500, respectively. European favorites Italy (+2,200), Switzerland (+1,500), Greece (+1,200) and Portugal (+800) all make it into this year’s Top 10 for net millionaire inflows along with Japan, which is on course to welcome 400 wealthy migrants, boosted in part by an accelerating trend of Chinese HNWIs moving to Tokyo that started post-Covid.

The other big millionaire losers in 2024

Besides China, the UK, India, South Korea, and Russia, the remaining places in the Top 10 millionaire outflow ranking are taken up by Brazil where a millionaire drain of 800 is projected this year, followed by South Africa (-600), Taiwan (-400), and Vietnam and Nigeria, which are both set to see 300 millionaires take flight.

But as Dr. Hannah White OBE, Director and CEO of the Institute for Government in London points out, HNWIs are leaving these other countries for quite different reasons from the UK: “Both China and India are seeing high net outflows because of the success of their sizeable economies in generating new millionaires, although slowing wealth growth in China in recent years could mean sustained losses become more damaging over time. As do those from many other developing nations, including notably Brazil, Vietnam, South Africa, and Nigeria, Indian millionaires often depart the sub-continent in search of a better lifestyle, safer and cleaner environments, and access to more premium health and education services. Elsewhere, regional threats and uncertainty over the security stance of America following a potential Trump victory in the 2024 US presidential election in November mean that South Korea and Taiwan are continuing to see net outflows of HNWIs.”

Advertisement
Stake.com

The surge in millionaire migration is fueling a corresponding boom in the investment migration sector. Henley & Partners has received record levels of enquiries about residence and citizenship by investment programs over the past 12 months from nearly 200 different countries. The top two nationalities currently driving demand are Americans and Indians, with Brits, Filipinos, and South Africans remaining in the Top 10 as they have done for the last five years.

Read the full press release.

View original content:https://www.prnewswire.co.uk/news-releases/millionaires-on-the-move-where-are-the-worlds-wealthy-migrating-to-and-from-in-2024-302172211.html

Continue Reading

Trending